News | December 17, 2025
Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
Subscribe To Our Newsletter & Stay Updated
